167 related articles for article (PubMed ID: 31788996)
1. ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience.
Amadio G; Marchetti C; Villani ER; Fusco D; Stollagli F; Bottoni C; Distefano M; Colloca G; Scambia G; Fagotti A
J Gynecol Oncol; 2020 Jan; 31(1):e6. PubMed ID: 31788996
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY; Urban RR; Liao JB; Goff BA
J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
Lorusso D; Marchetti C; Conte C; Giudice E; Bolomini G; Vertechy L; Ceni V; Ditto A; Ferrandina G; Raspagliesi F; Scambia G; Fagotti A
Gynecol Oncol; 2020 Oct; 159(1):95-100. PubMed ID: 32703631
[TBL] [Abstract][Full Text] [Related]
5. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in recurrent ovarian cancer.
Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
[TBL] [Abstract][Full Text] [Related]
11. Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
Fukuda T; Noda T; Uchikura E; Awazu Y; Tasaka R; Imai K; Yamauchi M; Ichimura T; Yasui T; Sumi T
Anticancer Res; 2023 Jul; 43(7):3097-3105. PubMed ID: 37351971
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
[TBL] [Abstract][Full Text] [Related]
13. Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study.
Gadducci A; Cosio S; Lissoni AA; Zizioli V; Adorni M; Ferrero AM; Landoni F; Sartori E
Anticancer Res; 2020 Mar; 40(3):1543-1550. PubMed ID: 32132055
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
18. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
